aTyr Pharma, Inc. (ATYR:NASDAQ) closed at $0.165 on October 23, 2026, down 2.88% on the day. The stock trades 85.1% below its 52-week high of $1.11 and 3.2% above its 52-week low of $0.160. Over the past year, it lost 82.9%. aTyr Pharma, Inc. is part of the Health Care sector.
In 252 trading sessions since October 23, 2025, ATYR closed higher on 108 days (43%). Its best day was May 14, 2026 (+41.41%) and its worst was May 12, 2026 (-44.21%). The stock moved 10% or more in a single session 15 times. It opened at least 5% above the previous day's high 3 times.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways. Its focus is on the extracellular functionality and signaling pathways of tRNA synthetases. It's lead clinical product candidate, ATYR1923, is a selective modulator of Neuropilin-2 (NRP2) that downregulates both the innate and adaptive immune responses in inflammatory disease states. It is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung diseases (ILDs), a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need.
Find more stocks like ATYR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.